.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

IRINOTECAN Drug Profile

« Back to Dashboard
Irinotecan is a drug marketed by Teva Pharms Usa, Sun Pharma Global, Hospira, Hisun Pharm Hangzhou, Cipla Ltd, Pliva Lachema, Akorn, Hikma Farmaceutica, Sandoz Inc, Dr Reddys Labs Ltd, Eurohlth Intl Sarl, Accord Hlthcare, Emcure Pharms Ltd, Jiangsu Hengrui Med, Fresenius Kabi Usa, Qilu Pharm Co Ltd, Fresenius Kabi Oncol, Actavis Totowa, Mustafa Nevzat Ilac, and Sandoz. and is included in twenty-one NDAs.

The generic ingredient in IRINOTECAN is irinotecan hydrochloride. There are thirty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mustafa Nevzat Ilac
IRINOTECAN HYDROCHLORIDE
irinotecan hydrochloride
INJECTABLE;INJECTION090393-003May 13, 2011RXNo<disabled><disabled>
Qilu Pharm Co Ltd
IRINOTECAN HYDROCHLORIDE
irinotecan hydrochloride
INJECTABLE;INJECTION203380-001May 3, 2016RXNo<disabled><disabled>
Jiangsu Hengrui Med
IRINOTECAN HYDROCHLORIDE
irinotecan hydrochloride
INJECTABLE;INJECTION090675-002Dec 16, 2011RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc